Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BPM 31510 + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BPM 31510 | BPM31510|BPM-31510 | BPM 31510 is a small molecule agent containing a formulation of co-enzyme Q10, thereby affecting metabolism via Warburg effect reversal and thus, potentially resulting in apoptotic activity of cancer cells (Cancer Res 2014;74(19 Suppl):Abstract nr 4321, PMID: 32807842). | ||
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04752813 | Phase II | BPM 31510 + Temozolomide | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | Active, not recruiting | USA | 0 |